Previous 10 | Next 10 |
A promising pipeline, collaborations with deep-pocketed partners, and adequate financing are some of the things investors look for in clinical-stage biopharma companies. AnaptysBio (NASDAQ: ANAB) offers most of those things, but has recently discovered that "promising pipeline" is a subjecti...
Shares of AnaptysBio (NASDAQ: ANAB) , a clinical-stage biopharmaceutical company, tumbled 10.3% today. Investors weren't impressed by top-line data for ANB019, the company's second most advanced new drug candidate. AnaptysBio announced top-line data from an interim analysis of the ongoing ph...
AnaptysBio (NASDAQ: ANAB ) has slipped 13.5% postmarket after posting some positive topline data from its interim analysis of the GALLOP Phase 2 clinical trial. More news on: AnaptysBio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy Patients demonstrated rapid and sustained mJDA score i...
SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
AnaptysBio (NASDAQ: ANAB ): Q2 GAAP EPS of -$0.89 beats by $0.10 . Revenue of $5M Press Release More news on: AnaptysBio, Inc., Earnings news and commentary, Healthcare stocks news,
Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2b Eosinophilic Asthma Trial Initiation Anticipated in 4Q19 IND Filing for Company’s Third Wholly-Owned Program, ANB030, an anti-PD-1 Agonist, Expected in 4Q19 Recog...
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...